phosphatidylinositol glycan anchor biosynthesis class C pseudogene 2Genealiases: []
Q-omics provides the consensus-scored PIGCP2 profile across patient tissues and cancer cell-line models. PIGCP2 expression is associated with patient survival in 8 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, PIGCP2 is differentially expressed in 3, with the highest sampling consensus in PRAD. Additionally, PIGCP2 RNA expression shows 7,214 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ACC, PRAD, and TGCT as cancer lineages where PIGCP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PIGCP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PIGCP2 survival associations across molecular data types. PIGCP2 RNA expression shows survival associations in the most cancer types (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PIGCP2 RNA expression–survival associations across cancer types. High PIGCP2 expression shows unfavorable associations in ACC, LIHC, CHOL, COAD, BLCA and OV. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for PIGCP2 RNA expression.
This table summarizes PIGCP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in PRAD for RNA.
This table ranks reproducible tumor–normal expression differences for PIGCP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PIGCP2 shows lower tumor expression in PRAD, COAD and LIHC. The PRAD box plot shows higher PIGCP2 RNA expression in normal versus tumor tissue (log2 FC = −0.213, t-test p = .020).
This table shows molecular features associated with PIGCP2 in patient tissues and cancer cell lines. In patient samples, PIGCP2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
